585544-20-3

Usage

Uses

Used in Pharmaceutical Research:
6-CHLORO-N-NEOPENTYLNICOTINIC ACID is used as a research compound for exploring its potential biological activity and applications in drug development. Its distinct structural features may contribute to the synthesis of novel pharmaceutical compounds.
Used in Drug Development:
In the pharmaceutical industry, 6-CHLORO-N-NEOPENTYLNICOTINIC ACID is utilized as a starting material or intermediate in the development of new drugs. Its unique properties could lead to the creation of innovative medications with improved therapeutic effects.
Further research is necessary to fully understand the properties and potential uses of 6-CHLORO-N-NEOPENTYLNICOTINIC ACID, ensuring its safe and effective application in the medical field.

Upstream product

• 58757-38-3 6-Chloronicotinoyl chloride 
• 5813-64-9 2.2-dimethylpropylamine 
• 6311-35-9 6-bromonicotinic acid 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 

Downstream Products

• 917223-75-7 N-(2,2-dimethylpropyl)-6-{3-fluoro-5-[(3-isoxazolylamino)carbonyl]-2-methylphenyl}-3-pyridinecarboxamide 
• 917223-81-5 3-(5-{[(2,2-dimethylpropyl)amino]carbonyl}-2-pyridinyl)-5-fluoro-4-methylbenzoic acid 
• 917223-88-2 methyl 3-(5-{[(2,2-dimethylpropyl)amino]carbonyl}-2-pyridinyl)-5-fluoro-4-methylbenzoate 
• 1033751-22-2 N-(2,2-dimethylpropyl)-6-(3-fluoro-2-methyl-5-{[(1-methyl-1H-pyrazol-5-yl)amino]carbonyl}phenyl)-3-pyridinecarboxamide 

Relevant academic research and scientific papers

A versatile biosynthetic approach to amide bond formation

The development of versatile and sustainable catalytic strategies for amide bond formation is a major objective for the pharmaceutical sector and the wider chemical industry. Herein, we report a biocatalytic approach to amide synthesis which exploits the diversity of Nature's amide bond forming enzymes, N-acyltransferases (NATs) and CoA ligases (CLs). By selecting combinations of NATs and CLs with desired substrate profiles, non-natural biocatalytic pathways can be built in a predictable fashion to allow access to structurally diverse secondary and tertiary amides in high yield using stoichiometric ratios of carboxylic acid and amine coupling partners. Transformations can be performed in vitro using isolated enzymes, or in vivo where reactions rely solely on cofactors generated by the cell. The utility of these whole cell systems is showcased through the preparative scale synthesis of a key intermediate of Losmapimod (GW856553X), a selective p38-mitogen activated protein kinase inhibitor.

Nucleophilic fluorination facilitated by a CsF-CaF2 packed bed reactor in continuous flow

A simple to prepare, dry and handle packed bed reactor carrying CsF on CaF2, towards nucleophilic fluorinations in continuous flow, is reported. The reactor also proved adaptable for silyl-ether deprotection and trifluoromethylations with Ruppert's reagent. The study includes reactor stability and scale-up investigations.

METHOD FOR SYNTHESISING AMIDES

The present invention relates to a method for synthesising amides that is of general applicability. The method may be performed in vitro or in vivo. Cell lines for use in the in vivo methods also form aspects of the invention. The method for synthesising a non-natural amide comprises: a. reaction of a carboxylic acid with a naturally occurring CoA ligase or a variant thereof; and b. reaction of the product of step a with an amine in the presence of a naturally occurring acyltransferase or a variant thereof; with the proviso that where the CoA ligase and acyltransferase are both naturally occurring, they are not derived from the same source species and do not act sequentially in a metabolic pathway; and with the proviso that the non-natural product is not N-(E)-p-coumaroyl-3-hydroxyanthranilic acid or N-(E)-p-caffeoyl-3-hydroxyanthranilic acid. Further, a method for producing an active pharmaceutical ingredient by the aforementioned method and host cells for carrying out said methods are envisaged.

p38α mitogen-activated protein kinase inhibitors: Optimization of a series of biphenylamides to give a molecule suitable for clinical progression

p38α MAP kinase is a key anti-inflammatory target for rheumatoid arthritis, influencing biosynthesis of pro-inflammatory cytokines TNFα and IL-1β at a translational and transcriptional level. In this paper, we describe how we have optimized a series of no

N-(2, 2-DIMETHYLPROPYL) -6- (3-FLUORO-5- ( (3-ISOXAZOLYLAMINO) CARBONYL) -2-METHYLPHENY L) -3-PYRIDINECARBOXAMIDE

The present invention relates to a novel compound, processes for its preparation, compositions comprising the same and its use in the treatment of condition or diseases mediated by p38 kinase activity.

3- AMINOCARBONYL, 6-PHENYL SUBSTITUTED PYRIDINE-1-OXIDES AS P38 KINASE INHIBITORS

Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.